Fourteen days after infusion of CD19-specific CAR-T cells, 11 juvenile ALL patients were boosted with pembrolizumab or nivolumab with optional repetition of PD-1 blocker infusion every 3 weeks [61]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.